vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a report published on Monday. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Alliance Global Partners started coverage on shares of vTv Therapeutics in a report on Monday, December 9th. They issued a “buy” rating and a $35.00 price target on the stock.

vTv Therapeutics Trading Down 0.2 %

Shares of NASDAQ:VTVT opened at $17.10 on Monday. vTv Therapeutics has a twelve month low of $12.12 and a twelve month high of $30.99. The company’s 50 day moving average is $16.22 and its 200 day moving average is $15.37. The company has a market cap of $54.55 million, a PE ratio of -3.77 and a beta of 1.07.

Institutional Investors Weigh In On vTv Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. FMR LLC acquired a new stake in shares of vTv Therapeutics during the 3rd quarter worth approximately $2,402,000. JPMorgan Chase & Co. acquired a new stake in shares of vTv Therapeutics during the 4th quarter worth approximately $25,000. Finally, Geode Capital Management LLC grew its stake in shares of vTv Therapeutics by 12.9% during the 4th quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock worth $158,000 after purchasing an additional 1,327 shares during the period. Institutional investors and hedge funds own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.